The Scottish Medicines Consortium has published advice accepting the use of Thousand Oaks, Calif.-based Amgen Inc.'s Kyprolis (carfilzomib) in combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The advice takes into account the continuing availability of the Patient Access Scheme agreed or a list price that is equivalent or lower.